Skip to content
OpenCapital
Get started

Solid Biosciences Inc. SLDB Operating lease liabilities

Operating lease liabilities at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
——
Scholar Rock logo
Scholar RockSRRK
——
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
——

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s operating lease liabilities?
Solid Biosciences Inc. (SLDB) reported operating lease liabilities of -$496K in Q1 2026.
How has Solid Biosciences Inc.'s operating lease liabilities changed year-over-year?
Solid Biosciences Inc.'s operating lease liabilities decreased by 19.2% year-over-year, from -$416K to -$496K.